Therapie des Typ-1-Diabetes

Aktualisierungshinweis

Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.

Publication History

Article published online:
24 December 2025

• Literatur

• 1 American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2017; 40 (Suppl. 01) S11-S24 . EK IV
• 2 Insel RA, Dunne JL, Atkinson MA. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38: 1964-1974 . EK IV/LoE 4
• 3 American Diabetes Association. Standards of Medical Care in Diabetes – 2018. Diabetes Care 2018; 41 (Suppl. 01) S13-S27 . EK IV
• 4 Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-1136 . EK III
• 5 Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283 . EK III
• 6 Palmer JP, Asplin CM, Clemons P. et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339 . EK III
• 7 Schlosser M, Mueller PW, Torn C. et al. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010; 53: 2611-2620 . EK III
• 8 Törn C, Mueller PW, Schlosser M. et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51: 846-852 . EK III
• 9 Wiest-Ladenburger U, Hartmann R, Hartmann U. et al. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 1997; 46: 565-571 . EK III
• 10 American Diabetes Association. Standards of Medical Care in Diabetes – 2017. Diabetes Care 2017; 40 (Suppl. 01) S4-S5 . EK IV
• 11 National Institute for Health and Clinical Excellence. Type 1 diabetes in adults: diagnosis and management. 2015 . EK IV
• 12 Miller KM, Beck RW, Bergenstal RM. et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care 2013; 36: 2009-2014 . EK Ib
• 13 Battelino T, Conget I, Olsen B. et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55: 3155-3162 . EK Ia
• 14 Battelino T, Phillip M, Bratina N. et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011; 34: 795-800 . EK Ia
• 15 Beck RW, Riddlesworth T, Ruedy K. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA 2017; 317: 371-378 . EK Ia
• 16 Benkhadra K, Alahdab F, Tamhane S. et al. Real-time continuous glucose monitoring in type 1 diabetes: A systematic review and individual patient data meta-analysis. Clin Endocrinol (Oxf) 2017; 86: 354-360 . EK Ia
• 17 Dicembrini I, Cosentino C, Monami M. et al. Effects of real-time continuous glucose monitoring in type 1 diabetes: A meta-analysis of randomized controlled trials. Acta Diabetol 2021; 58: 401-410 . EK 1a
• 18 Kamusheva M, Tachkov K, Dimitrova M. et al. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. Front Endocrinol (Lausanne) 2021; 12: 636959
• 19 Laffel LM, Kanapka LG, Beck RW. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2020; 323: 2388-2396 . EK Ia
• 20 Langeland LBL, Salvesen O, Selle H. et al. Short-term continuous glucose monitoring: effects on glucose and treatment satisfaction in patients with type 1 diabetes mellitus; a randomized controlled trial. Int J Clin Pract 2012; 66: 741-747 . EK Ia
• 21 Little SA, Leelarathna L, Walkinshaw E. et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014; 37: 2114-2122 . EK Ia
• 22 Maiorino MI, Signoriello S, Maio A. et al. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020; 43: 1146-1156 . EK Ia
• 23 Polonsky WH, Hessler D. What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users. Diabetes Technol Ther 2013; 15: 295-301 . EK III
• 24 Tumminia A, Crimi S, Sciacca L. et al. Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev 2015; 31: 61-68 . EK Ia
• 25 van Beers CAJ, DeVries JH. Continuous Glucose Monitoring: Impact on Hypoglycemia. J Diabetes Sci Technol 2016; 10: 1251-1258 . EK Ib
• 26 Beck RW, Kanapka LG, Breton MD. et al. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72. Diabetes Technol Ther 2023; 25: 329-342
• 27 Jiao Y, Lin R, Hua X. et al. A systematic review: Cost-effectiveness of continuous glucose monitoring compared to self-monitoring of blood glucose in type 1 diabetes. Endocrinol Diabetes Metab 2022; 5: e369 . EK Ia
• 28 Arbeitsgemeinschaft Diabetes & Technologie. Stellungnahme der Deutschen Diabetes Gesellschaft mit ihrer Arbeitsgemeinschaft Diabetes & Technologie zur Technischen Einweisung vs. Schulung in der Diabetologie: Definitionen und Abgrenzung der Leistungen am Beispiel rtCGM. Accessed September 11, 2023 at: https://diabetes-technologie.de/stellungnahme-zum-thema-technische-einweisung-vs-schulung-in-der-diabetologie
• 29 Boer de I, Kestenbaum B, Rue TC. et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch. Intern Med 2008; 168: 1867-1873 . EK Ib und EK IIa
• 30 Cleary PA, Orchard TJ, Genuth S. et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55: 3556-3565 . EK III
• 31 DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986 . EK Ib
• 32 Nathan DM, Cleary PA, Backlund JY. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653 . EK IIb
• 33 Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309 . EK Ib
• 34 White NH, Sun W, Cleary PA. et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707-1715 . EK III
• 35 Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Diabetes – Strukturierte Schulungsprogramme – Langfassung, 1. Auflage. Version 4. Accessed November 04, 2017 at: http://www.dm-schulung.versorgungsleitlinien.de . EK IV
• 36 Lipska KJ, Hirsch IB, Riddle MC. Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option. JAMA 2017; 318: 23-24 . EK IV/LoE 4
• 37 Lucidi P, Porcellati F, Marinelli Andreoli A. et al. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. Diabetes Care 2015; 38: 2204-2210 . EK IV
• 38 Wutte A, Plank J, Sinner F. Dose-response relationship and within-subject variability of insulin detemir and NPH insulin in subjects with Type 1 diabetes. Diabetes 2004; 53 (Suppl. 02) A152 . EK IV
• 39 Becker RHA, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 7-20 . EK III
• 40 Weyer C, Heise T, Heinemann L. Insulin Aspart in a 30/70 Premixed Formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614 . EK III
• 41 Woodworth JR, Howey DC, Bowsher RR. et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17: 366-371 . EK II
• 42 Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53: 787-800 . EK I
• 43 Heise T, Hövelmann U, Nosek L. et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 2015; 11: 1193-1201 . EK III
• 44 Nosek L, Coester H-V, Roepstorff C. et al. Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. Clin Drug Investig 2014; 34: 673-679 . EK II
• 45 Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes. Metab 2007; 9: 648-659 . EK I
• 46 Koehler G, Treiber G, Wutte A. et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes: 57–62; EK II. Diabetes Obes. Metab 2014; 16: 57-62 . EK II
• 47 Becker RHA, Dahmen R, Bergmann K. et al. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1: The ELEMENT 1 study. Diabetes Care 2015; 38: 637-643 . EK II
• 48 Shiramoto M, Eto T, Irie S. et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes. Metab 2015; 17: 254-260 . EK II
• 49 Heise T, Eckers U, Kanc K. et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: A randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008; 10: 479-485 . EK II
• 50 Heise T, Pieber TR, Danne T. et al. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clin Pharmacokinet 2017; 56: 551-559 . EK II
• 51 Famulla S, Hovelmann U, Fischer A. et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care 2016; 39: 1486-1492 . EK II
• 52 Kazda C, Leohr J, Liu R. et al. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study. Diabetes Obes Metab 2022; 24: 196-203 . EK Ib
• 53 Heise T, Weyer C, Serwas A. et al. Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin. Diabetes Care 1998; 21: 800-803 . EK III
• 54 Rave K, Heinemann L, Puhl L. et al. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Diabetes Care 1999; 22: 865-866 . EK III
• 55 Brunner M, Pieber T, Korsatko S. et al. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes. Drugs Aging 2015; 32: 583-590 . EK II
• 56 Heise T, Nosek L, Roepstorff C. et al. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Ther 2014; 5: 255-265 . EK II
• 57 Pease A, Lo C, Earnest A. et al. Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis. Diabetes Care 2020; 43: 1967-1975 . EK Ia
• 58 Franz MJ, MacLeod J, Evert A. et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. J Acad Nutr Diet 2017; 117: 1659-1679 . EK 1
• 59 Fu S, Li L, Deng S. et al. Effectiveness of advanced carbohydrate counting in type 1 diabetes mellitus: A systematic review and meta-analysis. Sci Rep 2016; 6: 37067
• 60 MacLeod J, Franz MJ, Handu D. et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations. J Acad Nutr Diet 2017; 117: 1637-1658 . EK 1a
• 61 Sterner Isaksson S, Bensow Bacos M, Eliasson B. et al. Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial. BMJ Open Diabetes Res Care 2021; 9: e001971 . EK 1b
• 62 Vaz EC, Porfírio GJM, Nunes HRdC. et al. Effectiveness and safety of carbohydrate counting in themanagement of adult patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Arch Endocrinol Metab 2018; 62: 337-345 . EK 1a
• 63 Kulzer B, Albus C, Herpertz S. et al. Psychosoziales und Diabetes (Teil 1). Diabetologie und Stoffwechsel 2013; 8: 198-242 . EK IV
• 64 Kulzer B, Albus C, Herpertz S. et al. Psychosoziales und Diabetes (Teil 2). Diabetologie und Stoffwechsel 2013; 8: 292-324 . EK IV
• 65 Hermanns N, Kulzer B, Krichbaum M. Problemspezifische Patientenschulung. Übersicht zu einem wesentlichen Bestandteil der Diabetestherapie. Diabetologe 2008; 4: 361-367 . EK III
• 66 van Duinkerken E, Snoek FJ, Wit de M. The cognitive and psychological effects of living with type 1 diabetes: A narrative review. Diabet Med 2020; 37: 555-563 . EK Ib
• 67 Skinner TC, Joensen L, Parkin T. Twenty-five years of diabetes distress research. Diabet Med 2020; 37: 393-400 . EK Ib
• 68 Fisher L, Polonsky WH, Hessler D. Addressing diabetes distress in clinical care: A practical guide. Diabet Med 2019; 36: 803-812
• 69 Holt RIG, DeVries JH, Hess-Fischl A. et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2021; 64: 2609-2652 . EK Ib
• 70 Donihi AC. Practical Recommendations for Transitioning Patients with Type 2 Diabetes from Hospital to Home. Curr Diab Rep 2017; 17: 52
• 71 Nassar CM, Montero A, Magee MF. Inpatient Diabetes Education in the Real World: An Overview of Guidelines and Delivery Models. Curr Diab Rep 2019; 19: 103
• 72 Baldwin D, Zander J, Munoz C. et al. A randomized trial of two weightbased doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012; 35: 1970-1974
• 73 Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N. et al. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Cochrane Database Syst Rev 2018; 11: CD011296
• 74 Dhatariya K, Corsino L, Umpierrez GE. Endotext. Management of Diabetes and Hyperglycemia in Hospitalized Patients. South Dartmouth (MA): 2000
• 75 Iyengar R, Franzese J, Gianchandani R. Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis. Curr Diab Rep 2018; 18: 75
• 76 Sadhu AR, Patham B, Vadhariya A. et al. Outcomes of “Real-World” Insulin Strategies in the Management of Hospital Hyperglycemia. J Endocr Soc 2021; 5: bvab101
• 77 Petrie JR, Chaturvedi N, Ford I. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 597-609 . EK Ib/LoE 1-
• 78 Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176 . EK III
• 79 Canadian Diabetes Association. 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Accessed July 23, 2017 at: http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf . EK IV
• 80 Dhatariya KK, Glaser NS, Codner E. et al. Diabetic ketoacidosis. Nat Rev Dis Primers 2020; 6: 40
• 81 Karges B, Rosenbauer J, Holterhus P-M. et al. Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31330 young patients with type 1 diabetes. Eur J Endocrinol 2015; 173: 341-350
• 82 Schellhaas B, Haak T. Diabetische Ketoazidose – erkennen, behandeln, vermeiden. Diabetologie 2022; 18: 669-676
• 83 Haak T, Kellerer M. Deutsche Diabetes-Gesellschaft. Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Mainz: Kirchheim; 2009. . EK IV
• 84 Kitabchi AE, Umpierrez GE, Murphy MB. et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29: 2739-2748 . EK IV
• 85 Umpierrez G, Korytkowski M. Diabetic emergencies – ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol 2016; 12: 222-232
• 86 Kitabchi AE, Umpierrez GE, Miles JM. et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32: 1335-1343 . EK IV
• 87 Bull SV, Douglas IS, Foster M. et al. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial. Crit Care Med 2007; 35: 41-46 . EK IIb
• 88 Gosmanov AR, Gosmanova EO, Kitabchi AE. Endotext. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State.
• 89 van Zyl DG, Rheeder P, Delport E. Fluid management in diabetic-acidosis-Ringer’s lactate versus normal saline: A randomized controlled trial. QJM 2012; 105: 337-343
• 90 Joint British Diabetes Societies for inpatient care. The Management of Diabetic Ketoacidosis in Adults. Second Edition Update: September 2013. Accessed September 23, 2017 at: http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_DKA_Adults_Revised.pdf . EK IV